Clinical, Medical & Diagnostic Products


Controlled Drug Destruction Kit for Secure Drug Denaturation


saferdestruct24 the new Controlled Drug Destruction Kit from Safer Options will give you complete confidence in your controlled drug disposal procedures, even in high-risk environments. Available form Alpha Laboratories, these new kits are an innovative and unique solution helping hospitals, pharmacies, hospices, care homes and other healthcare providers to safely manage waste medicines and comply with legislation more easily and effectively.


No other supplier can make the claim of 100% drug destruction. saferdestruct24 is the most destructive drug containment kit commercially available - the only kit with 100% morphine destruction in 24 hours, which means less storage time before disposal for you.


Reducing the risk of user contamination, saferdestruct24 controlled drug destruction kits are simple, safe and easy to use. Waste medicines are placed in the jar with the water-soluble sachet of destruction formula. Water is then added to the designated level and the jar closed and shaken to mix the contents. The formula colour change provides you with a visual check that destruction is taking place. The kit contents congeal and the destroyed drugs can be placed in pharmaceutical waste 24 hours later.


Full instructions are printed on every container so there is no pack insert to get lost, especially when splitting up multipacks for use in separate locations.


saferdestruct24 controlled drug destruction kits are manufactured in the UK and components locally sourced, plus the 250ml kit is produced using post-consumer recycled plastic, so you’ll be doing your bit to help the environment too.


The kits are available in six container volumes and a range of pack sizes providing multiple options to suit your working needs. More information online: ilmt.co/PL/50nL


56402pr@reply-direct.com


Aptamers for Targeting SARS-CoV-2 Proteins


AMSBIO has further expanded its product range to help in the fight against COVID-19 with the introduction of a new range of aptamers targeting SARS-CoV-2 proteins to aid development of new kits and assays.


Aptamers are small single-stranded RNA or DNA oligonucleotides that fold in a three-dimensional conformation allowing them to bind specifically to a target. This target can be an organic molecule, free or carried in cells or tissues, or inorganic components, such as metal ions. Aptamers have generated significant interest as promising tools, that compete with monoclonal antibodies, for detection and inhibition of specific markers of human diseases because they offer high specificity for their target, no to low immunogenicity and easy in vitro selection.


To better understand the genetic architecture of host proteins interacting with SARS-CoV-2 or mediating host response to COVID-19 - using an aptamer-based technique can help to identify new or repurpose existing drugs targeting those proteins.


As aptamers bind targets with high selectivity and specificity, they are an ideal tool to help develop new approaches to early-stage diagnostic assay and adequate therapy. With AMSBIO aptamers targeting SARS-CoV-2 S1 protein, S2 protein, RBD protein or nucleocapsid protein, they can be used in wide range of detection methods and for development of COVID-19 diagnostic assays.


Contact AMSBIO to learn more about the new range of aptamers targeting SARS-CoV-2 proteins. More information online: ilmt.co/PL/GaP0 56340pr@reply-direct.com


European Study Finds MDW Biomarker Provides Earlier Sepsis Detection


Beckman Coulter announced the results of a prospective study carried out across two European hospitals, which found that Monocyte Distribution Width (MDW), in combination with White Blood Cell Count with Differential (WBC), has the diagnostic accuracy to detect the risk of sepsis and severe infection upon patient presentation in A&E, particularly when assessed in patients with a lower likelihood of sepsis. The study analysed 1,517 adult patients in the accident and emergency departments of France’s largest hospital, the Pitié-Salpêtrière APHP-Sorbonne Université hospital in Paris, and the Hospital Universitari Germans Trias i Pujol in Badalona, in Spain, the results of which were recently published in medical journal Critical Care.


The study found that that abnormal MDW values, when considered along with the standard physiologic parameters at the time of patient presentation in the emergency department, increased the odds of Sepsis-2 by factor of 5.5 and Sepsis-3 by 7.6 Additionally, MDW was found to increase incrementally with progression from milder forms of infection to sepsis and is highest in those with septic shock.


“Early detection of sepsis is warranted to initiate specific goal-directed therapy bundles,” said Pierre Hausfater, MD, PhD, Professor of Emergency Medicine at Sorbonne Université and principal investigator in the study. Unlike Procalcitonin (PCT) and C-reactive Protein (CRP), which are usually ordered only in patients with a clinical suspicion for infection or sepsis, MDW and WBC are available early as a part of routine CBC-DIFF. Because of this, MDW may have a role of enhancing the routinely used CBC-DIFF to identify and reclassify the patients at risk, without changes to the current workflow of early clinical evaluation.”


Study researchers also proposed the clinical role of MDW as a systematic screening test for sepsis where an abnormal MDW can trigger commonly ordered sepsis workup tests for inflammatory biomarkers PCT or CRP.


“The results of the study support the implementation of MDW in emergency labs as an initial test used to identify patients at risk of infection or sepsis, which may then prompt additional tests, thus providing a better care process,” said Dr Cristian Morales Indiano, MD of the Laboratory Medicine Department at Hospital Universitari Germans Trias i Pujol in Badalona, in Spain.


Testing and screening for the novel MDW hematologic biomarker is available on the Beckman Coulter DxH 900 and DxH 690T Haematology Analysers as a part of a CBC-DIFF.


To read the full study, visit: ilmt.co/PL/eMWg More information online: ilmt.co/PL/Ekd9


56382pr@reply-direct.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56